The aim of this study was to evaluate the applicability of American Thoracic Society and European Respiratory Society criteria for spirometry in children.Maximal expiratory flow/volume (MEFV) measurements from 446 school-age children, experienced in performing MEFV manoeuvres, were studied and acceptability (start-of-test (backward extrapolated volume as a percentage of forced vital capacity (FVC) (Vbe%FVC) or as an absolute value (Vbe), end-of-test (forced expiratory time (FET)) and reproducibility criteria (absolute and percentage difference between best and second-best FVC and forced expiratory volume in one second (FEV1) (DFVC, DFVC %, DFEV1 and DFEV1 %)) were applied to these manoeuvres.The Vbe%FVC criterion was met by 91.5%, the Vbe v0.15 L criterion by 94.8% and the Vbe v0.10 L by 60.1% of children. Vbe v0.15 L appeared to be a more useful parameter than Vbe%FVC. The FET criterion was met by only 15.3% of children. DFVC v0.2 L and DFEV1 v0.2 L were met by 97.1% and 98.4%, and DFVC v0.1 L and DFEV1 v0.1 L by 79.8% and 84.3% of the children, respectively. These criteria appeared to be less useful compared to percentage criteria (DFVC % and DFEV1 %). Even experienced children did not meet all international criteria for spirometry. However, most of their MEFV curves are useful for interpretation.Based on the performance of these children, a re-evaluation of criteria for maximal expiratory flow/volume measurements in children is proposed.
Bronchiolitis is a common disorder in young children that often results in hospitalisation. Except for a possible effect of nebulised hypertonic saline (sodium chloride), no evidence-based therapy is available. This study investigated the efficacy of nebulised 3% and 6% hypertonic saline compared with 0.9% hypertonic saline in children hospitalised with viral bronchiolitis.In this multicentre, double-blind, randomised, controlled trial, children hospitalised with acute viral bronchiolitis were randomised to receive either nebulised 3%, 6% hypertonic saline or 0.9% normal saline during their entire hospital stay. Salbutamol was added to counteract possible bronchial constriction. The primary endpoint was the length of hospital stay. Secondary outcomes were need for supplemental oxygen and tube feeding.From the 292 children included in the study (median age 3.4 months), 247 completed the study. The median length of hospital stay did not differ between the groups: 69 h (interquartile range 57), 70 h (IQR 69) and 53 h (IQR 52), for 3% (n584) and 6% (n583) hypertonic saline and 0.9% (n580) normal saline, respectively, (p50.29). The need for supplemental oxygen or tube feeding did not differ significantly. Adverse effects were similar in the three groups.Nebulisation with hypertonic saline (3% or 6% sodium chloride) although safe, did not reduce the length of stay in hospital, duration of supplemental oxygen or tube feeding in children hospitalised with moderateto-severe viral bronchiolitis. @ERSpublications Hypertonic saline nebulisation did not reduce hospital stay for children with viral bronchiolitis
This study was designed to evaluate the value and applicability of tidal breathing pattern analysis to assess airflow obstruction in young children. The time needed to reach maximal tidal expiratory flow (TME) divided by total expiratory time (TE) was measured in 228 healthy children 3 to 11 yr of age, 64 patients with asthma, and 12 children with cystic fibrosis. In 70 patients both TME/TE and forced maximal expiratory flow volume (MEFV) parameters were measured. The mean TME/TE in healthy subjects was 43.0 +/- 7.6%. The within-subject reproducibility was high (repeatability index, 5.3%). In the asthmatic patients the mean TME/TE was significantly lower (30.0 +/- 8.2%, p < 0.001), and it increased to 36.5 +/- 7.9% after bronchodilation (n = 44, p < 0.001). The TME/TE level of the subgroup of patients with asthma and FEV1/FVC > or = 0.80 was lower when compared with age-matched normal subjects (30.9 +/- 8.5, p < 0.0001), but it was in a higher range when compared with asthmatics with FEV1/FVC < 0.80 (25.9 +/- 7.9, p < 0.001). In the cystic fibrosis group the mean TME/TE was 27.4 +/- 10.7% without a significant change after bronchodilation. TME/TE correlated significantly with MEFV parameters. Tidal breathing analysis proved easy to perform in children older than 3 yr of age. The TME/TE ratio may be a reliable and simple indicator for airway obstruction.
Chronic inflammation and extracellular remodeling of the airway wall characterize asthma. The purpose of this study was to examine whether these features cause a change in airway mechanical properties. We examined 14 healthy and 10 young adults with long-lasting asthma, the latter treated with inhaled bronchodilators and corticosteroids. To obtain area-versus-transmural pressure (A-Ptm) curves during forced expiration (Pedersen, O. F., et al. J. Appl. Physiol. 1982;52:357-369), we used an esophageal balloon and a Pitot static probe positioned at five locations between the right lower lobe and midtrachea. Cross-sectional area (A), airway compliance (Caw = dA/dPtm), and specific airway compliance (sCaw = Caw/A) were obtained from the A-Ptm curves. Results showed that: (1) A was larger in males than in females; (2) Caw and sCaw decreased with a more downstream position; and (3) Caw and sCaw were significantly lower in the patients with asthma, with the differences between the asthmatic patients and the healthy subjects becoming smaller toward the trachea. The lower Caw and sCaw in the patients with long-lasting asthma support the concept that chronic inflammation and remodeling of the airway wall may result in stiffer dynamic elastic properties of the asthmatic airway.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.